Cargando…

Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study

BACKGROUND: To date, the value of hyperthermic intraperitoneal chemotherapy (HIPEC) following up-front resection for isolated synchronous colorectal peritoneal metastases seems controversial. PATIENTS AND METHODS: This retrospective cohort study was conducted from September 1, 2012, to September 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xiusen, Siyad Mohamed, Mohamed, Zhang, Yuanxin, Chen, Yuefang, Wu, Zhijie, Luo, Rui, Yi, Liang, Wang, Hui, Wang, Huaiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623104/
https://www.ncbi.nlm.nih.gov/pubmed/36330501
http://dx.doi.org/10.3389/fonc.2022.959514
_version_ 1784821921371652096
author Qin, Xiusen
Siyad Mohamed, Mohamed
Zhang, Yuanxin
Chen, Yuefang
Wu, Zhijie
Luo, Rui
Yi, Liang
Wang, Hui
Wang, Huaiming
author_facet Qin, Xiusen
Siyad Mohamed, Mohamed
Zhang, Yuanxin
Chen, Yuefang
Wu, Zhijie
Luo, Rui
Yi, Liang
Wang, Hui
Wang, Huaiming
author_sort Qin, Xiusen
collection PubMed
description BACKGROUND: To date, the value of hyperthermic intraperitoneal chemotherapy (HIPEC) following up-front resection for isolated synchronous colorectal peritoneal metastases seems controversial. PATIENTS AND METHODS: This retrospective cohort study was conducted from September 1, 2012, to September 1, 2019, at a tertiary medical center in China. Patients with isolated synchronous colorectal peritoneal metastases were included in CRS plus HIPEC group or CRS alone group based on the treatment history. Overall survival and relapse-free survival were estimated using Cox proportional hazards regression analysis and Kaplan–Meier method. RESULTS: 78 patients with isolated synchronous colorectal peritoneal metastases were identified among 396 patients with synchronous colorectal peritoneal metastases. 43 were in the cytoreductive surgery plus HIPEC group and 35 were in the cytoreductive surgery alone group. Among them, 61 patients had relapse-free survival data. The median peritoneal cancer index was 4 in all patients. After a median follow-up of 46.0 months, 5-year overall survival was 66.8% and the median relapse-free survival was 36.0 (95% CI, 6.8-65.1) months in the CRS plus HIPEC group. 5-year overall survival was 31.2% and the median relapse-free survival was 12.0 (95% CI, 9.0-15.0) months in the CRS alone group. Cox regression analyses showed that HIPEC was the independent prognostic factor for overall survival (P = 0.004) and relapse-free survival (P = 0.049). CONCLUSION: Findings of the present study suggest that HIPEC following up-front CRS could improve overall survival and relapse-free survival in patients with isolated synchronous colorectal peritoneal metastases.
format Online
Article
Text
id pubmed-9623104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96231042022-11-02 Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study Qin, Xiusen Siyad Mohamed, Mohamed Zhang, Yuanxin Chen, Yuefang Wu, Zhijie Luo, Rui Yi, Liang Wang, Hui Wang, Huaiming Front Oncol Oncology BACKGROUND: To date, the value of hyperthermic intraperitoneal chemotherapy (HIPEC) following up-front resection for isolated synchronous colorectal peritoneal metastases seems controversial. PATIENTS AND METHODS: This retrospective cohort study was conducted from September 1, 2012, to September 1, 2019, at a tertiary medical center in China. Patients with isolated synchronous colorectal peritoneal metastases were included in CRS plus HIPEC group or CRS alone group based on the treatment history. Overall survival and relapse-free survival were estimated using Cox proportional hazards regression analysis and Kaplan–Meier method. RESULTS: 78 patients with isolated synchronous colorectal peritoneal metastases were identified among 396 patients with synchronous colorectal peritoneal metastases. 43 were in the cytoreductive surgery plus HIPEC group and 35 were in the cytoreductive surgery alone group. Among them, 61 patients had relapse-free survival data. The median peritoneal cancer index was 4 in all patients. After a median follow-up of 46.0 months, 5-year overall survival was 66.8% and the median relapse-free survival was 36.0 (95% CI, 6.8-65.1) months in the CRS plus HIPEC group. 5-year overall survival was 31.2% and the median relapse-free survival was 12.0 (95% CI, 9.0-15.0) months in the CRS alone group. Cox regression analyses showed that HIPEC was the independent prognostic factor for overall survival (P = 0.004) and relapse-free survival (P = 0.049). CONCLUSION: Findings of the present study suggest that HIPEC following up-front CRS could improve overall survival and relapse-free survival in patients with isolated synchronous colorectal peritoneal metastases. Frontiers Media S.A. 2022-10-18 /pmc/articles/PMC9623104/ /pubmed/36330501 http://dx.doi.org/10.3389/fonc.2022.959514 Text en Copyright © 2022 Qin, Siyad Mohamed, Zhang, Chen, Wu, Luo, Yi, Wang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Xiusen
Siyad Mohamed, Mohamed
Zhang, Yuanxin
Chen, Yuefang
Wu, Zhijie
Luo, Rui
Yi, Liang
Wang, Hui
Wang, Huaiming
Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title_full Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title_fullStr Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title_full_unstemmed Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title_short Hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: A retrospective, observational study
title_sort hyperthermic intraperitoneal chemotherapy following up-front cytoreductive surgery versus cytoreductive surgery alone for isolated synchronous colorectal peritoneal metastases: a retrospective, observational study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623104/
https://www.ncbi.nlm.nih.gov/pubmed/36330501
http://dx.doi.org/10.3389/fonc.2022.959514
work_keys_str_mv AT qinxiusen hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT siyadmohamedmohamed hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT zhangyuanxin hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT chenyuefang hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT wuzhijie hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT luorui hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT yiliang hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT wanghui hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy
AT wanghuaiming hyperthermicintraperitonealchemotherapyfollowingupfrontcytoreductivesurgeryversuscytoreductivesurgeryaloneforisolatedsynchronouscolorectalperitonealmetastasesaretrospectiveobservationalstudy